Drugs that block the HIF2-responsive growth factor VEGF (vascular endothelial growth factor) or its receptor KDR (kinase-domain related) are now mainstays of ccRCC treatment 7. This evidence concerns the gene VEGFA and nonpapillary renal cell carcinoma.